242 related articles for article (PubMed ID: 32718045)
1. Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know.
Bol KF; Donia M; Heegaard S; Kiilgaard JF; Svane IM
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718045
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.
Griewank KG; Murali R; Schilling B; Scholz S; Sucker A; Song M; Süsskind D; Grabellus F; Zimmer L; Hillen U; Steuhl KP; Schadendorf D; Westekemper H; Zeschnigk M
Br J Cancer; 2013 Jul; 109(2):497-501. PubMed ID: 23799844
[TBL] [Abstract][Full Text] [Related]
3. BRAF mutations are detectable in conjunctival but not uveal melanomas.
Spendlove HE; Damato BE; Humphreys J; Barker KT; Hiscott PS; Houlston RS
Melanoma Res; 2004 Dec; 14(6):449-52. PubMed ID: 15577314
[TBL] [Abstract][Full Text] [Related]
4. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
Larsen AC
Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
[TBL] [Abstract][Full Text] [Related]
5. Lack of BRAF mutations in uveal melanoma.
Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
[TBL] [Abstract][Full Text] [Related]
6. Genetic findings in treatment-naïve and proton-beam-radiated iris melanomas.
Krishna Y; Kalirai H; Thornton S; Damato BE; Heimann H; Coupland SE
Br J Ophthalmol; 2016 Jul; 100(7):1012-1016. PubMed ID: 27098748
[TBL] [Abstract][Full Text] [Related]
7. The T1799A point mutation is present in posterior uveal melanoma.
Janssen CS; Sibbett R; Henriquez FL; McKay IC; Kemp EG; Roberts F
Br J Cancer; 2008 Nov; 99(10):1673-7. PubMed ID: 18985043
[TBL] [Abstract][Full Text] [Related]
8. A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib.
Maleka A; Åström G; Byström P; Ullenhag GJ
BMC Cancer; 2016 Aug; 16():634. PubMed ID: 27520988
[TBL] [Abstract][Full Text] [Related]
9. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.
Edmunds SC; Cree IA; Dí Nícolantonío F; Hungerford JL; Hurren JS; Kelsell DP
Br J Cancer; 2003 May; 88(9):1403-5. PubMed ID: 12778069
[TBL] [Abstract][Full Text] [Related]
10. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
Maat W; Kilic E; Luyten GP; de Klein A; Jager MJ; Gruis NA; Van der Velden PA
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):23-7. PubMed ID: 18172070
[TBL] [Abstract][Full Text] [Related]
11. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
12. The T1799A BRAF mutation is present in iris melanoma.
Henriquez F; Janssen C; Kemp EG; Roberts F
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):4897-900. PubMed ID: 17962436
[TBL] [Abstract][Full Text] [Related]
13. [THE BRAF MUTATION AND THE POSSIBILITIES OF UVEAL MELANOMA METASTASING PROGNOSTIC MARKERS IDENTIFICATION].
Horkovičová K; Markus J; Krčová I; Babál P; Kobzová D; Smolková B
Cesk Slov Oftalmol; 2016; 72(4):149-156. PubMed ID: 27860480
[TBL] [Abstract][Full Text] [Related]
14. Genetics of Ocular Melanoma: Insights into Genetics, Inheritance and Testing.
van Poppelen NM; de Bruyn DP; Bicer T; Verdijk R; Naus N; Mensink H; Paridaens D; de Klein A; Brosens E; Kiliҫ E
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396957
[TBL] [Abstract][Full Text] [Related]
15. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
[TBL] [Abstract][Full Text] [Related]
16. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea.
Weber A; Hengge UR; Urbanik D; Markwart A; Mirmohammadsaegh A; Reichel MB; Wittekind C; Wiedemann P; Tannapfel A
Lab Invest; 2003 Dec; 83(12):1771-6. PubMed ID: 14691295
[TBL] [Abstract][Full Text] [Related]
17. Lack of BRAF mutation in primary uveal melanoma.
Cohen Y; Goldenberg-Cohen N; Parrella P; Chowers I; Merbs SL; Pe'er J; Sidransky D
Invest Ophthalmol Vis Sci; 2003 Jul; 44(7):2876-8. PubMed ID: 12824225
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
[TBL] [Abstract][Full Text] [Related]
19. BRAF mutations in conjunctival melanoma.
Gear H; Williams H; Kemp EG; Roberts F
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2484-8. PubMed ID: 15277467
[TBL] [Abstract][Full Text] [Related]
20. SOX10 Expression as Well as BRAF and GNAQ/11 Mutations Distinguish Pigmented Ciliary Epithelium Neoplasms From Uveal Melanomas.
Mori T; Sukeda A; Sekine S; Shibata S; Ryo E; Okano H; Suzuki S; Hiraoka N
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5445-5451. PubMed ID: 29059311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
